Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Holdings Lessened by Braun Stacey Associates Inc.

Braun Stacey Associates Inc. reduced its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 5.0% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 22,146 shares of the biopharmaceutical company’s stock after selling 1,172 shares during the quarter. Braun Stacey Associates Inc.’s holdings in Regeneron Pharmaceuticals were worth $23,281,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. International Assets Investment Management LLC increased its holdings in shares of Regeneron Pharmaceuticals by 86,013.3% in the 3rd quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock worth $926,078,000 after acquiring an additional 879,916 shares during the period. Capital International Investors increased its holdings in shares of Regeneron Pharmaceuticals by 7.3% in the 1st quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company’s stock worth $3,011,640,000 after acquiring an additional 213,038 shares during the period. Price T Rowe Associates Inc. MD increased its holdings in shares of Regeneron Pharmaceuticals by 25.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 902,613 shares of the biopharmaceutical company’s stock worth $868,757,000 after acquiring an additional 184,561 shares during the period. Swedbank AB acquired a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter worth about $129,257,000. Finally, Epoch Investment Partners Inc. acquired a new position in Regeneron Pharmaceuticals during the 1st quarter valued at about $99,667,000. 83.31% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

REGN has been the subject of several research reports. Citigroup initiated coverage on shares of Regeneron Pharmaceuticals in a research report on Thursday. They set a “neutral” rating and a $895.00 price objective for the company. Truist Financial decreased their price target on shares of Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a “buy” rating for the company in a report on Friday, November 1st. Leerink Partnrs cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. BMO Capital Markets cut their price objective on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating on the stock in a research report on Friday, November 1st. Finally, StockNews.com lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 4th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $1,099.55.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the transaction, the chief financial officer now owns 15,305 shares in the company, valued at $18,447,575.65. This trade represents a 27.07 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 7.48% of the stock is owned by company insiders.

Regeneron Pharmaceuticals Trading Down 3.3 %

NASDAQ REGN opened at $756.81 on Monday. Regeneron Pharmaceuticals, Inc. has a 12 month low of $753.69 and a 12 month high of $1,211.20. The stock has a 50 day moving average of $985.21 and a 200-day moving average of $1,034.89. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. The company has a market cap of $83.17 billion, a PE ratio of 18.73, a PEG ratio of 2.86 and a beta of 0.15.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.